MarginsXMarginsX
Home › Markets › Health Care › TRLV

Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV)

TRLV trades on NYSE in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$10.33
-5.23% on the day
Market cap
$2.0B
Small cap
Revenue · 2025
$1.2B
-0.4% on 2024
Net income · 2025
-$122.2M
-10.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1754195/000175419526000019/0001754195-26-000019-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTRLV on NYSE
SectorHealth Care
Industry Medicinal Chemicals and Botanical Products
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001754195
SEC industry codeMedicinal Chemicals & Botanical Products
Incorporated inBC

Financials · 2025

LineValue
Revenue$1.2B
Net income-$122.2M
Operating income$143.5M
Net margin-10.3%
Operating margin12.1%
Revenue growth-0.4%
Cash$255.5M
Total assets$2.7B
P/E (computed)Net income was not positive
P/S (computed)1.7×

Warning signs

Cash runway
Cash-flow positive
$326.7M cash at September 30, 2026
Share count, 1 year
-10.7%
2025-10-31 to 2026-10-30
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$14.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$326.7M cash; operating cash flow $60.6M a quarter.Report 2026-09-30
Shares outstanding170,631,619 (2026-10-30); 191,158,338 a year earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWithumSmith+Brown, PC, New York, New York, United StatesPCAOB Form AP 2026-02-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $14.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$230.2M$774K$74.4M$326.7M$196.0M$1.1B10-Q 2026-11-05
Q2 2026
2026-06-30
$271.0M-$406.1M$53.1M$325.4M$195.8M$1.1B10-Q 2026-08-07
Q1 2026
2026-03-31
$286.8M$2.3M$55.7M$352.9M$195.6M$1.2B10-Q 2026-05-07
Q4 2025
2025-12-31
$293.1M-$43.6M$59.2M$255.5M$136.7M$1.2B10-K 2026-02-26
Q3 2025
2025-09-30
$288.2M-$28.8M$76.4M$449.2M$366.1M$1.2B10-Q 2026-11-05
Q2 2025
2025-06-30
$302.1M-$16.1M$86.1M$392.6M$365.7M$1.2B10-Q 2026-08-07
Q1 2025
2025-03-31
$297.8M-$33.8M$51.1M$328.5M$365.3M$1.2B10-Q 2026-05-07
Q4 2024
2024-12-31
$301.1M-$61.6M$30.7M$238.8M$364.8M$1.2B10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2025-06-30
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEF 14A2026-06-25

Source: SEC EDGAR submissions feed, 416 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.7%
1 month+7.8%
3 months+13.5%
Year to date+25.4%
1 year+77.2%
From 52-week high-16.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Medicinal Chemicals and Botanical Products

TickerCompanyPriceDayMarket cap
RLXRLX Technology Inc.$1.53-1.92%$1.9B
RGCRegencell Bioscience Holdings Limited$4.72-4.45%$2.3B
CRONCronos Group Inc. Common Share$3.27-3.25%$1.2B
DFTXDefinium Therapeutics Inc. Common Shares$30.16-5.99%$4.1B
OBIOOrchestra BioMed Holdings Inc.$7.12-1.79%$560.4M
TLRYTilray Brands Inc. Common Stock$2.34-3.70%$345.8M
SNDLSNDL Inc. Common Shares$1.34-2.19%$326.0M
ACBAurora Cannabis Inc. Common Shares$4.61-6.68%$303.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier